Tablets & Capsules

TC0419

Issue link: https://www.e-digitaleditions.com/i/1101841

Contents of this Issue

Navigation

Page 21 of 55

20 April 2019 Tablets & Capsules mers that are not particularly water soluble, so they could potentially change the product's drug-release behavior. Conversely, many coatings that are readily water soluble might prove less effective as taste-mask- ing agents, especially when administering the final dos- age form in the types of food products listed. As a result, balancing both pharmacokinetic and taste-mask- ing requirements can be a challenge. To illustrate how developers might address this challenge, a recent study examined the application of a specialized water-soluble film coating (Aquarius Protect) to mini-tablets containing cetirizine hydro- chloride (20 percent drug content) [3]. For the sake of comparison, the study also evaluated a conventional HPMC-based film coating (Aquarius Prime). Each coating was applied at levels ranging from 10 to 30 percent (based on substrate weight) respectively, using an O'Hara laboratory-scale fluid-bed coater fitted with a Wurster insert and employing the coating process conditions listed in Table 2. To assess the applied coatings' taste-masking capabili- ties, the study examined pure API, uncoated tablets con- taining the API, and both coated placebo and coated API-containing mini-tablets using an Astree e-Tongue system equipped with an Alpha MOS sensor set (com- prising seven specific sensors: ZZ, AB, BA, BB, CA, DA, and JE). The sensors act as a surrogate for human taste buds, measuring changes in electric potentials that can be compared to physiological action potentials. This method allows researchers to examine the relative taste-masking effectiveness of formulation approaches, identifying the most likely candidates for ultimate assess- ment in human taste-masking studies. Test results are typically presented in the form of a principal component map. To interpret the results, it's necessary to assess the degree of separation between the pure API and uncoated samples containing the API and the coated API- containing samples (the further the degree of separation, the better). It's also necessary to study the relative close- ness between the coated API-containing samples and the similarly coated placebo samples (in this case, the greater the similarity, the better). is <1.2, well below the visually detectable limit for this yellow color). In addition, coated tablet quality was more than acceptable, as shown in Figure 5. Meeting the challenges of pediatric dosage form development Historically, pediatric oral drug products were typi- cally offered in the form of syrups or chewable tablets. More recently, regulatory agencies have placed greater demands on the development process, requiring that pediatric dosage forms be designed to meet the special needs of young patients. These requirements include that: • The final product can be easily divided to match an individual patient's dosage requirements (depending on age, body size, and the particular disease state being treated). • The formulation is effectively taste masked to facili- tate compliance with the physician's and pharma- cist's instructions. Additionally, the taste-masking method should not compromise the pharmacoki- netic characteristics of the API (that is, taste mask- ing should not change the product's drug release characteristics unless there is a specific requirement to do so). • The developer conducts appropriate stability studies in cases where the final dose may need to be administered in food products, such as yogurt or applesauce. Referring to the second requirement, taste masking has traditionally involved applying a polymer coating to a suitable dosage form (often in the form of multi- particulates). While many coatings can produce effec- tive taste-masking characteristics, they often use poly- Table 2 Process conditions for coating mini-tablets (O'Hara fluid-bed coater fitted with a Wurster insert) Inlet air temperature (°C) Product temperature (°C) Spray rate (g/min) Atomizing air pressure (psi) Air volume (cfm) 62-65 44-46 8-10 28-30 62-65 Figure 5 Coated tablet quality using a GEA ConsiGma coater a. 25 percent solids d. 35 percent solids c. 32.5 percent solids b. 30 percent solids While many coatings can produce effective taste-masking characteristics, they often use polymers that are not particularly water soluble, so they could potentially change the product's drug-release behavior.

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC0419